alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 99.1



Certifications of Chief Executive Officer
and Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002



I, Robert J. Zollars, certify that, to the best of my knowledge based upon a review of the Form 10-K, the Form 10-K fully complies with
the requirements of Section 13(a) of the Exchange Act and that information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Neoforma, Inc. for the periods covered by the Form
10-K.



|Dated:    March 28, 2003 |  | By: |  | /s/    ROBERT J.
ZOLLARS
|------------------------ |  | --- |  | ------------------------
|                         |  |     |  |                         



I,
Andrew L. Guggenhime, certify that, to the best of my knowledge based upon a review of the Form 10-K, the Form 10-K fully complies with the requirements of Section 13(a) of the Exchange Act and that information contained in the Form 10-K fairly
presents, in all material respects, the financial condition and results of operations of Neoforma, Inc. for the periods covered by the Form 10-K.



|Dated:    March 28, 2003 |  | By: |  | /s/    ANDREW L.
GUGGENHIME
|------------------------ |  | --- |  | ---------------------------
|                         |  |     |  |                            



A signed
original of this written statement required by Section 906 has been provided to Neoforma, Inc. and will be retained by Neoforma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit
32.1
  CERTIFICATION
PURSUANT TO
 18
U.S.C. SECTION 1350,
 AS
ADOPTED PURSUANT TO
 SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
 
 In
connection with the Annual Report of Royal Quantum Group, Inc. a Nevada
corporation (the "Company") on Form 10-K for the year ending December 31, 2008,
as filed with the Securities and Exchange Commission on the date hereof (the
"Report"), Ron Ruskowsky, Chief Executive Officer of the Company, certifies to
the best of his knowledge, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
 
 (1)
              The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and
 
 (2)
              The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and result of operations of the
      Company.
 
 A signed
original of this written statement required by Section 906 has been provided to
Royal Quantum Group, Inc., and will be retained by Royal Quantum Group, Inc. and
furnished to the Securities and Exchange Commission or its staff upon
request.
  /s/
      Ron RuskowskyRon
      Ruskowsky
                    Chief
      Executive and Financial Officer
                    March
      30, 2009
#### STATE v. CANTY

No. 15 PC.

Case below: 22 N.C. App. 45.

Petition for writ of certiorari to North Carolina Court of Appeals denied 30 August 1974.
**Exhibit 23.2**

 

Notice Regarding Consent of Arthur Andersen LLP

 

Section 11(a) of the Securities Act of 1933, as amended (the Securities Act), provides that if any part of a registration statement at thetime such part becomes effective contains an untrue statement of a material fact or an omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, any person acquiring a securitypursuant to such registration statement (unless it is proved that at the time of such acquisition such person knew of such untruth or omission) may sue, among others, every accountant who has consented to be named as having prepared or certified anypart of the registration statement, or as having prepared or certified any report or valuation which is used in connection with the registration statement, with respect to the statement in such registration statement, report or valuation whichpurports to have been prepared or certified by the accountants. 

 

This Form 10-Kis incorporated by reference into a NutriSystem, Inc. filing on Form S-8 No. 333-44908 (the Registration Statement) and, for purposes of determining any liability under the Securities Act, is deemed to be a new registration statement for eachRegistration Statement into which it is incorporated by reference. 

 

On July 3,2002, NutriSystem dismissed Arthur Andersen LLP as its independent auditor and appointed KPMG LLP to replace Arthur Andersen. Since NutriSystem’s former engagement partner and audit manager have left Andersen and in light of the cessation ofAndersen’s SEC practice, NutriSystem has been unable to obtain Andersen’s written consent to the incorporation by reference into the Registration Statement of its audit report with respect to NutriSystem’s financial statements as ofDecember 31, 2001 and 2000 and for the years then ended. Under these circumstances, Rule 437a under the Securities Act permits NutriSystem to file this Form 10-K without a written consent from Arthur Andersen. As a result, however, Arthur Andersenwill not have any liability under Section 11(a) of the Securities Act for any untrue statements of a material fact contained in the financial statements audited by Andersen or any omission of a material fact required to be stated therein.Accordingly, you would be unable to assert a claim against Andersen under Section 11(a) of the Securities Act for any purchases of securities under the Registration Statement made on or after the date of this Form 10-K. To the extent provided inSection 11(b) (3) (C) of the Securities Act, however, other persons who are liable under Section 11(a) of the Securities Act, including the Company’s officers and directors, may still rely on Andersen’s original audit reports as being madeby an expert for purposes of establishing a due diligence defense under Section 11 (b) of the Securities Act.
Exhibit
10.6


 


EMPLOYMENT
AGREEMENT AMENDMENT


 


THIS
EMPLOYMENT AGREEMENT AMENDMENT (this “Amendment”) is entered into effective as of January 1, 2020 (the “Effective
Date”), between Rhino GP LLC (“Employer”) and Chad Hunt (“Employee”).


 


W
I T N E S S E T H


 


WHEREAS,
Employee is currently employed by Employer pursuant to an Amended and Restated Employment Agreement dated August 31, 2014 (as
amended, the “Prior Agreement”).


 


WHEREAS,
Employer and Employee now desire to amend the Prior Agreement, and have executed this Amendment to evidence the terms of their
agreement.


 


NOW,
THEREFORE, in consideration of the mutual covenants herein contained, the parties agree as follows:


 


1.
Section 1 of the Prior Agreement is hereby deleted and replaced in its entirety with the following language:


 


“Terms
of Employment. Unless terminated earlier in accordance with the provisions of Section 7, Executive’s employment under
this Agreement shall be effective for a term commencing on the Effective Date and ending on December 31, 2020 (the “Employment
Term”).”


 


2.
All other terms and conditions in the Prior Agreement shall remain unchanged except to the extent specifically modified herein.


 


[SIGNATURE
PAGE TO FOLLOW]


 




    	1



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have executed and delivered this Amendment as of the day and year first above written.


 


	 	EMPLOYER:
	 	 
	 	Rhino
    GP LLC
	 	 	 
	 	By:	/s/
    Richard A. Boone


 


	 	EMPLOYEE:
	 	 
	 	/s/
    Chad Hunt
	 	 
	 	Chad
    Hunt


 




    	2
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT BY
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of GFR Pharmaceuticals, Inc. on Form 10-KSB
for the year ending December 31, 2004, as filed with the Securities and Exchange
Commission on the date hereof (the "Report"), I, Richard Pierce, Chief Executive
Officer of the Company,  certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the  Sarbanes-Oxley Act of 2002, that, to the best of
my knowledge and belief:

         (1) the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) the  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and result of  operations of the
Company.



By: /s/ Richard Pierce
Richard Pierce, CEO, Director
Date: April 13, 2005

A signed  original of this written  statement  required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the  electronic  version of this written  statement
has been  provided  to the  Company  and will be  retained  by the  Company  and
furnished to the Securities  and Exchange  Commission or its staff upon request.
The foregoing  certifications  are  accompanying the Company's Form 10-KSB soley
pursuant to section 906 of the  Sarbanes-Oxley  Act of 2002 (subsections (a) and
(b) of section  1350,  chapter 63 of title 18,  United  States  Code) and is not
being filed as part of the Form 10-KSB or as a separate disclosure document.
#### WISE v. WISE

No. 273 PC.

Case below: 42 N.C. App. 5.

Petition by plaintiff for discretionary review under G.S. 7A-31 denied 25 September 1979.
Fourth Court of Appeals

San Antonio, Texas

September 26, 2014

No. 04-14-00397-CV

IN THE INTEREST OF S.D.A., S.A.A., D.S.A., Children,

From the 37th Judicial District Court, Bexar County, Texas

Trial Court No. 2013EM506191

Honorable Eric Rodriguez, Judge Presiding

ORDER

The Appellant’s Request for Extension of Time to File Brief is GRANTED. The

appellant’s brief is due on October 13, 2014.

_________________________________

Rebeca C. Martinez, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 26th day of September, 2014.

___________________________________

Keith E. Hottle

Clerk of Court
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF FLORIDA

GAINESVILLE DIVISION

VICKIE LEE,

Plaintiff,

v. CASE NO.: 1:10cv22-SPM/AK

SHANDS AT LAKE SHORE, INC.,

Defendant.

_____________________________/

ORDER EXTENDING TIME TO RESPOND TO COMPLAINT

Upon consideration, Defendant’s Unopposed Motion for an Extension of

Time to Respond to the Complaint (doc. 8) is granted. Defendant shall have up

to and including April 14, 2010, to file and serve its response to the complaint.

SO ORDERED this 9th day of April, 2010.

 s/ Stephan P. Mickle 

Stephan P. Mickle

Chief United States District Judge
Exhibit 32.1



                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with the Quarterly  Report of Keystone  Consolidated  Industries,
Inc. (the  "Company") on Form 10-Q for the quarter ended March 31, 2006 as filed
with the Securities and Exchange  Commission on the date hereof (the  "Report"),
we, David L. Cheek,  President and Chief Executive  Officer of the Company,  and
Bert E.  Downing,  Jr.,  Vice  President,  Chief  Financial  Officer,  Corporate
Controller and Treasurer of the Company,  certify, pursuant to 18 U.S.C. Section
1350,  as adopted  pursuant  to Section 906 of the  Sarbanes-Oxley  Act of 2002,
that:

     (1) The Report fully  complies  with the  requirements  of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and result of  operations of the
Company.




/s/  David L. Cheek                     /s/  Bert E. Downing, Jr.
-------------------------------------   -------------------------
David L. Cheek                          Bert E. Downing, Jr.
President and Chief Executive Officer   Vice President, Chief Financial Officer,
May 15,2006                             Corporate Controller and Treasurer
                                        May 15, 2006



Note: The certification  the registrant  furnishes in this exhibit is not deemed
"filed" for purposes of Section 18 of the  Securities  Exchange Act of 1934,  as
amended,  or otherwise subject to the liabilities of that Section.  Registration
Statements or other documents filed with the Securities and Exchange  Commission
shall not incorporate this exhibit by reference,  except as otherwise  expressly
stated in such filing.
Exhibit 32.1



      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF TEHE SARBANES-OXLEY ACT OF 2002


I,  Thomas  Cooke,  certify,  pursuant  to 18 U.S.C.  Section  1350,  as adopted
pursuant  to  Section  906 of the  Sarbanes-Oxley  Act of 2002,  that the Annual
Report of Saratoga  Resources,  Inc. on Form 10-KSB for the year ended  December
31, 2004 fully complies with the  requirements  of Section 13(a) or 15(d) of the
Securities  Exchange  Act of 1934 and that  information  contained  in such Form
10-KSB  fairly  presents in all material  respects the  financial  condition and
results of operations of Saratoga Resources, Inc.


                                          By:   /S/ Thomas Cooke
                                                _____________________________
                                          Name: Thomas Cooke
                                          Title: Chief Executive Officer and
                                                 Chief Financial Officer
                                          Dated: July 8, 2005
##### 



EXHIBIT 99.2 BARCLAYCARD FUNDING PLCS OFFICERS CERTIFICATE GRACECHURCH RECEIVABLES TRUSTEE LIMITED
CERTIFICATE OF COMPLIANCE The undersigned officer of Barclaycard Funding PLC, a private limited liability
company incorporated under the laws of Jersey, Channel Islands (the MTN
Issuer), hereby certifies on behalf of the MTN Issuer and on his own behalf
for purposes of the Investor Certificate, as follows:  1.
    
    I am a duly appointed, qualified and acting Director of the MTN Issuer;2.
    
    I am duly authorized to execute and deliver this Officers Certificate on behalf of the MTN Issuer; and3.
    
    To the best of my knowledge, the MTN Issuer has complied with all conditions and covenants under the
Relevant Documents for the issue of the Investor Certificate for the period between December 15, 2002
and December 31, 2003. Capitalized terms used and not defined herein shall have the meanings assigned
to such terms in the Registration Statement related to the above-referenced
issue of Investor Certificate. IN WITNESS WHEREOF, I have signed my name this 21st day of June, 2004. By:
    
    /s/ Richard Francis SommersName: Richard Francis SommersTitle: Director
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Lancer
Orthodontics, Inc. second quarter fiscal 1996 10-QSB and is qualified in its
entirety by reference to such 10-QSB.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAY-31-1996
<PERIOD-END>                               NOV-30-1995
<CASH>                                         161,184
<SECURITIES>                                         0
<RECEIVABLES>                                1,413,096
<ALLOWANCES>                                   130,568
<INVENTORY>                                  1,682,782
<CURRENT-ASSETS>                             3,186,157
<PP&E>                                       2,461,417
<DEPRECIATION>                               2,128,070
<TOTAL-ASSETS>                               4,090,834
<CURRENT-LIABILITIES>                          904,290
<BONDS>                                        423,538
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    185,242
<COMMON>                                     4,677,556
<OTHER-SE>                                 (2,099,792)
<TOTAL-LIABILITY-AND-EQUITY>                 4,090,834
<SALES>                                      3,472,902
<TOTAL-REVENUES>                             3,472,902
<CGS>                                        1,937,619
<TOTAL-COSTS>                                1,937,619
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              36,299
<INCOME-PRETAX>                                188,877
<INCOME-TAX>                                       800
<INCOME-CONTINUING>                            188,077
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   188,077
<EPS-PRIMARY>                                     .012
<EPS-DILUTED>                                     .012
        

</TABLE>
Case 1:07-cv-03583-LBS-RLE     Document 22-17      Filed 04/28/2008     Page 1 of 5

Case 1:07-cv-03583-LBS-RLE     Document 22-17      Filed 04/28/2008     Page 2 of 5

Case 1:07-cv-03583-LBS-RLE     Document 22-17      Filed 04/28/2008     Page 3 of 5

Case 1:07-cv-03583-LBS-RLE     Document 22-17      Filed 04/28/2008     Page 4 of 5

Case 1:07-cv-03583-LBS-RLE     Document 22-17      Filed 04/28/2008     Page 5 of 5
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                         338,074
<SECURITIES>                                         0
<RECEIVABLES>                                  188,665
<ALLOWANCES>                                  (36,485)
<INVENTORY>                                  1,384,289
<CURRENT-ASSETS>                             1,893,936
<PP&E>                                       3,978,176
<DEPRECIATION>                               2,747,164
<TOTAL-ASSETS>                               3,202,042
<CURRENT-LIABILITIES>                       18,147,764
<BONDS>                                      2,173,499
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    924,525
<COMMON>                                       286,723
<OTHER-SE>                                (18,330,469)
<TOTAL-LIABILITY-AND-EQUITY>                 3,202,042
<SALES>                                      1,322,090
<TOTAL-REVENUES>                             1,322,090
<CGS>                                        2,011,174
<TOTAL-COSTS>                                5,910,711
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                               175,000
<INTEREST-EXPENSE>                           1,002,735
<INCOME-PRETAX>                            (5,591,356)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (5,591,356)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (5,591,356)
<EPS-BASIC>                                      (.20)
<EPS-DILUTED>                                    (.20)










</TABLE>
<PAGE>

                                                                EXHIBIT 99.1
                                                                ------------



                 K-V PHARMACEUTICAL COMPANY AND SUBSIDIARIES


                          CERTIFICATION PURSUANT TO
                           18 U.S.C. SECTION 1350
                           AS ADOPTED PURSUANT TO
                SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of K-V Pharmaceutical Company (the
"Company") on Form 10-Q for the period ending December 31, 2002 as filed
with the Securities and Exchange Commission on the date hereof (the
"Report"), I, Marc S. Hermelin, Vice Chairman and Chief Executive Officer of
the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to
ss. 906 of the Sarbanes-Oxley Act of 2002, that:

     (1) The Report fully complies with the requirements of section 13(a) or
         15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
         material respects, the financial condition and result of operations
         of the Company.



/s/ Marc S. Hermelin
-----------------------------------------
Marc S. Hermelin
Vice Chairman and Chief Executive Officer
January 17, 2003
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health;

      ( print page 55786)    
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Heart, Lung, and Blood Institute Special Emphasis Panel, NIH Research Scientist Development Awards (K01's).                    

*Date:*                         October 26, 2007.                    

*Time:*                         8 a.m. to 3 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Brookshire Suites, 120 East Lombard Street, Baltimore, MD  21202.                    

*Contact Person:*                         Chang Sook Kim, PhD, Scientific Review Administrator, Review Branch, DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7190, Bethesda, MD  20892-7924, 301-435-0287,                         *carolko@mail.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: September 21, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07-4822 Filed 9-28-07; 8:45 am]

BILLING CODE 4140-01-M